ADMA Biologics: Bollinger Bands Narrowing, KDJ Death Cross on 15-Min Chart

The 15-minute chart of ADMA Biologics has triggered a narrowing of Bollinger Bands and a KDJ Death Cross at 09/30/2025 15:00. This indicates a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, which may lead to further decreases in the stock price.

Adma Biologics (ADMA), a biotechnology company focusing on infectious disease treatments, has experienced a notable decline in its stock price. As of the latest trading session, ADMA closed at $15.32, down by 2.17% from the previous day. This decline was more pronounced than the broader market indices, with the S&P 500, Dow, and Nasdaq all losing around 0.5% to 0.38%.

Over the past month, ADMA has underperformed relative to the Medical sector and the S&P 500. The company's shares have fallen by 9.22%, while the Medical sector lost only 0.7% and the S&P 500 gained 2.74%. This underperformance has drawn attention to the company's upcoming earnings report, scheduled for the near future.

Analysts predict ADMA to post an earnings per share (EPS) of $0.16 for the quarter, representing a 6.67% growth compared to the same period last year. Revenue is expected to reach $130.1 million, up 8.56% year-over-year. These estimates are part of the company's Zacks Consensus Estimates, which project full-year earnings of $0.57 per share and revenue of $506.7 million, indicating year-over-year growth of 16.33% and 18.82%, respectively.

In addition to the financial outlook, technical indicators have raised concerns. On September 30, 2025, the 15-minute chart of ADMA triggered a narrowing of Bollinger Bands and a KDJ Death Cross. These signals indicate a decrease in the magnitude of price fluctuations and a shift in momentum towards the downside, potentially leading to further price declines.

Analysts have noted recent revisions in estimates for ADMA, reflecting a changing outlook on the company's business health and profitability. The Zacks Rank system, which considers these estimate changes, currently rates ADMA as a "Hold" (#3), suggesting moderate investment potential. The company's Forward P/E ratio of 27.47 also indicates a premium valuation relative to the industry average of 19.43.

Investors should monitor ADMA's upcoming earnings report and technical indicators to gauge the company's performance and potential stock movements. Zacks Investment Research provides a comprehensive platform for tracking these metrics and other relevant data.